News

Accell Evo3 is said to be the latest generation in demineralized bone matrix and is composed of an optimized blend of particulate demineralized bone matrix (DBM), the proprietary

Mr Hobbs is president and CEO of AngioDynamics, a medical device company specializing in the development and sales of medical technology serving the needs of interventional oncologists and

The milestone was triggered by Progenics’s initiation of a Phase I clinical trial with its prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) for patients with hormone-refractory prostate cancer.

A separate efficacy supplement that included data from patients with cutaneous T-cell lymphoma (CTCL) whose malignant cells did not test positive for the CD25 component of the IL-2

This double-blind, placebo-controlled Phase I study (Study 290-001), is expected to enroll up to 60 adult healthy volunteers. MGCD290 will be administered orally at an initial starting dose

Lorus has also announced that Central America has been added to the territories covered in the exclusive licensing agreement with Zor Pharmaceuticals. Due to the extension of the

Palifosfamide, the active moiety of ifosfamide (IFOS), is a bi-functional alkylator that causes irreparable inter-strand DNA cross-linking, resulting in cell death. Palifosfamide is equal to or more active

The SEEplate cervical plate system incorporates features that are aimed at allowing surgeons an alternative to confirming the secure placement of the anti-back-out mechanism of screws used as

As a result of the acquisition, GlaxoSmithKline (GSK) will become the leading pharmaceutical company in Egypt with a market share of approximately 9%. GSK will acquire 20 branded